A prominent functional change during differentiation of lutein cells from follicular thecal and granulosa cells is an enhanced production and secretion of progestins. The regulation of this process is not fully understood but may be associated with the expression of transcription factors which activate genes, products of which are involved in pathways of the cholesterol and lipid metabolism. As peroxisome proliferator-activated receptors (PPARs) play a role in both pathways, we were interested in the expression of PPAR , a PPAR form which is involved in adipogenic differentiation. First, we were able to show the expression of PPAR in bovine lutein cells (day 12 of the ovarian cycle) at the mRNA and protein level by imaging, flow cytometry and blot analysis, and secondly a role of PPAR in the secretion of progesterone. The cells (24 h culture) responded dose dependently by increasing progesterone secretion (up to 1·5-fold of the basal level) to an endogenous ligand of PPAR , 15-deoxy-12,14 prostaglandin J 2 (15-dPGJ 2 ) and to the thiazolidinedione ciglitizone. Aurintricarboxylic acid (ATA) was found to reduce the intracellular PPAR level and to promote cell cycle progress, indicating that ATA can be used as a tool for experimental changes of PPAR proteins in intact cells and for studying the physiological consequences. The ATA-mediated decrease of PPAR was accompanied by reduced progesterone production and a progression of the cell cycle, suggesting a function of PPAR in both processes. The response to ATA was abrogated by a high dose (>490 nM) of 15-dPGJ 2 , suggesting that 15-dPGJ 2 exerts its effect on steroidogenic activity via PPAR and that the 15-dPGJ 2 -PPAR system plays a role in the maintenance of a differentiated quiescent stage in lutein cells.
Introduction
Lutein cells develop from follicular-theca and granulosa cells into small and large cells which lose their proliferative activity, stop oestrogen production (Monniaux et al. 1994) and enhance their steroidogenic activity for progestin secretion (Goldring et al. 1986 , Doody et al. 1990 . The altered function is accompanied by a change in the expression of enzymes involved in steroidogenic activity (Doody et al. 1990 ). This implies regulatory events at the transcriptional level. However, the underlying mechanism is not known.
Peroxisome proliferator-activated receptors (PPARs) are transcription factors and part of the nuclear receptor superfamily that includes receptors for steroids, thyroid hormones and retinoids (Issemann & Green 1990 , Schmidt et al. 1992 . The PPARs act by binding to specific sequences (hormone response elements) in the promoter region of the target genes (Gulick et al. 1994 , Schoonjans et al. 1995 . The receptors are inactive in the absence of their activating hormone ligand and in the absence of retinoid receptors (RXR). The transcription is activated subsequent to heterodimerisation of PPAR and RXR. This occurs after binding of the respective ligands by the ligand-binding domains (Keller et al. 1993) . In the case of PPAR , 15-deoxy-12,14 prostaglandin J 2 (15-dPGJ 2 ) is the natural ligand and 9-cis retinoic acid is the ligand for RXR (Forman et al. 1995 , Kliewer et al. 1995 . The prostaglandin is intracellularly synthesised via the arachidonic acid-PGD 2 -PGJ 2 pathway (Fukushima 1992 ). This pathway is regulated by the rate-limiting enzymes of the group A 2 phospholipases (Dennis 1994) which are active in corpora lutea (Sawada & Carlson 1991) .
Together with another group of transcription factors, the sterol receptor element binding proteins (SREBP), which have been shown to regulate intracellular cholesterol homeostasis (Brown & Goldstein 1997) , PPARs mediate the induction of some genes which encode mitochondrial rate-limiting enzymes of cholesterol and fatty acid metabolism (Gulick et al. 1994 , Rodriguez et al. 1994 , a prerequisite for the PPARs' role in the regulation of cellular steroidogenic activity. More recently the expression of the PPAR form of the PPARs was demonstrated at mRNA level in the corpus luteum (Nunez et al. 1997) and PPAR mRNA was detected in bovine lutein cells (Sundvold et al. 1997) , whereas information about the expression at the protein level and the function of PPAR in lutein cells is apparently lacking. We demonstrate here the expression of PPAR in bovine midphase lutein cells at mRNA and protein level, and the involvement of PPAR in regulation of progesterone secretion and in the maintenance of a quiescent differentiated stage of lutein cells.
Materials and Methods

Chemicals and biochemicals
PPAR antibodies and 15-dPGJ 2 were obtained from Cayman-Alexis (Grünberg, Germany), the thiazolidinedione (ciglitizone) from Biomol (Hamburg, Germany) and the anti-phosphotyrosine antibodies from BoehringerMannheim (Mannheim, Germany). All other chemicals, hormones, and antibodies were from Sigma Chemical Co. (Deisenhofen, Germany) where not otherwise stated.
Cells
The study was focused on day 12 lutein cells, as in the midphase cycle the progesterone secretion remains high, indicative of intact cell function. Despite functional integrity, morphological changes occur, including accumulation of lipid droplets (Fields et al. 1992) indicative of metabolic changes thought to be regulated by PPAR in other cell systems (Keller et al. 1993 , Kliewer et al. 1995 . However, to compare the levels of expression, some experiments were also carried out using day 5 lutein cells. Corpora lutea were obtained by ovariectomy, which was performed on day 5 and 12 (three animals in each case) of the oestrous cycle (oestrous=day 0) in epiduraland locally anaesthetised cows in accordance with the German Federal Law for Care of Animals. The corpora lutea were surgically removed. The tissue was placed on gauze (60 µm pores), minced, and gently ground with a glass rod, covering the tissue with Ham F12 medium buffered with Hepes (25 mM, pH 7·4) and containing 2 mM EDTA to facilitate cell dissociation. The cell suspension was filtered, the cells spun off (200 g, 10 min), and erythrocytes lysed by resuspending the cells in water. Lysis was stopped after 10 s by adding concentrated saline to achieve 0·85% saline. After centrifugation the cells were resuspended in serum-free, EDTA-free, Hepes-buffered Ham F12 with 10 ng/ml insulin (culture medium). Cell density was determined by a cell counter (Coulter, Krefeld, Germany), cell viability by exclusion of trypan blue or 40 µM propidium iodide (PI). PI uptake was checked by flow cytometry; the viability was >95%. Aliquots (10 6 cells/ml) were plated in 24-well and 96-well culture plates (Greiner, Frinckenhausen, Germany) without and with additives as indicated in Results. Granulosa cells from follicles 5 1 mm in diameter (two ovaries from two animals) were checked for the expression of PPAR in order to gather some information about the specificity of PPAR expression. The cells were obtained by aspiration of the follicle as previously described (Tiemann et al. 1993) . Then they were fixed and immunostained as described for lutein cells.
Progesterone assay
Progesterone concentrations (in culture medium or in serum to check the oestrous cycle) were measured in a direct RIA. Dilution curves of the samples were parallel to the standard curve. The intra-and interassay coefficients of variation were 8 and 11%. The detection limit was 15 pg/ml. Progesterone from lutein cells was expressed as the amount of hormone secreted by 10 6 viable cells per 24 h.
Luteinising hormone (LH) receptor detection
To explore the level of PPAR -mediated steroidogenic regulation by PPAR ligands, the expression of LH receptors, a prerequisite for cAMP-mediated regulation of the steroidogenesis in lutein cells, was measured. Ovine LH (2·5 IU/mg, Sigma) was fluoresceinated with a commercial kit (Sigma). The procedure followed the recommendations of the manufacturer with the modification that the buffer for fluorescein isothiocyanate (FITC) conjugation was 50 mM Na phosphate (pH 7·8) in 200 mM NaCl so that 60-70% of the biological activity of LH was maintained after fluoresceination (about 2 molecules FITC/molecule LH). Day 12 cells were incubated with FITC-LH (2-20 µg/10 5 cells per ml PBS, pH 7·3, with 2 mg/ml BSA and 0·1% NaN 3 ). FITC-LH binding was saturable and displaced (65-73%) by unlabelled LH (200-fold excess) in cells size-gated by flow cytometry.
Phenotyping
Large lutein cells were identified by flow cytometry (Coulter, Elite) according to size and granularity. The size was determined by measuring the time of flight on the peak forward scatter signal. The data were identical with those obtained by relating the forward scatter signals to standard beads (Coulter). The latter approach was routinely used. The bulk of the large, size-gated cells (16 4 µm) expressed LH receptors (59-70%, the variation was due to individual differences), indicating lutein cell phenotype.
Cell cycle analysis
Cells were fixed in ethanol (70%), washed and treated with RNAase (1 mg/ml in PBS, 37 C, 30 min) after denaturation of DNases by heating (85 C, 60 min) the RNAase solution (Stöhr et al. 1978) . After incubation for 30 min with PI (70 µM) in 5 mM Hepes, pH 7·3, in 150 mM NaCl, flow cytometry was performed (Coulter, Elite) and the cell cycle was analysed by a computer-aided Multicycle Program (Phoenix, San Diego, CA, USA).
Western blot
Cells were lysed by cold aqueous 0·1% sodium citrate with 0·1% Triton X-100; the lysate was fractionated by centrifugation (1000 g, 10 min, 4 C and 110 000 g, 1 h, 4 C). The supernatant of the ultracentrifugate was immediately placed on PAGE and the separated proteins were blotted onto nitrocellulose as described . PPAR was detected by commercial rabbit anti-PPAR antibodies to the PPAR amino acid sequence 284-298. Staining was developed by peroxidaseconjugated anti-rabbit F(ab ) 2 and densitometry was performed as described . Phosphorylation was detected by anti-phosphotyrosine antibodies to phosphorylated tyrosine moieties of proteins according to the instructions of the manufacturer. The antibodies did not react with nucleotides, phosphoserine, phosphothreonine or phosphohistidine as tested by the manufacturer (Boehringer-Mannheim).
PPAR detection in cells
Lutein cells were fixed in methanol ( 20 C) for 4 min, using 1 volume lutein cell suspension (10 6 cells/ml) and 10 volumes methanol. The cells were spun off (150 g, 0 C, 5 min), resuspended in PBS containing 0·2% BSA (pH 7·4), and aliquots were plated (24-well plastic microplates). The cells were incubated (2 h, 22 C) with rabbit anti-PPAR antibodies used at a final dilution of 1:400, and the non-bound antibodies were washed out. Next, the cells were incubated for 2 h at 22 C with phycoerythrinconjugated anti-rabbit F(ab ) 2 antibody fragments (PBS, pH 7·2, 0·2% BSA, 1 mM EDTA). The fluorescence was quantified by flow cytometry.
Flow cytometry
Quantitative analysis of cellular fluorescence was performed by flow cytometry to analyse the cells simultaneously according to size, granularity, LH receptors, and PPAR expression (portion of cells expressing PPAR and PPAR content per cell). The analysis was analogous to a described method (Löhrke et al. 1997) . Briefly, an argon laser-equipped flow cytometer (Coulter, Elite) recording emissions of multiple fluorescence (green, orange, red) excited at 488 nm (counting 5000 cells) was used. Cells of interest were identified by three successive steps: (1) by establishing a histogram on the basis of cell size and granularity, (2) by establishing the fluorescence histogram, and (3) by projecting the fluorescence into the sizegranularity histogram. The cells were gated and the portion of cells and their fluorescence intensity arising from a second fluorogenic label were automatically calculated.
PPAR degradation
Day 12 lutein cells (10 6 /ml) were incubated without and with 10 µM actinomycin D to block de novo synthesis of proteins and 10 µM aurintricarboxylic acid (ATA) for 24 h in culture medium. ATA was used because preliminary experiments showed the drug to inhibit the expression of PPAR . After incubation, cells were fixed in methanol and immunostained as described above. Non-specific fluorescence obtained by omitting the PPAR -specific antibody was automatically subtracted, recording the percentage of fluorescence positive cells and the fluorescence intensity per cell. By calibrating the fluorescence intensity by standard beads (26 p, Flow Cytometry Standards Corporation, Leiden, The Netherlands) the amount of PPAR per cell was calculated. The assumptions for the calculation were that, according to the instructions of the manufacturer, the ratio of label to antibody was 3-4:1 (molecules:molecule) and the ratio of binding between rabbit anti-PPAR and anti-rabbit F(ab) 2 antibody was 2:1 (molecules:molecule), that the rabbit anti-PPAR antibody recognises a single epitope defined by the amino acid sequence 284-298 of the PPAR molecule, and that the dissociation rate of high affinity antibodies is negligible.
RNA and cDNA
For the preparation of total RNA a commercial kit (Quiagen, Hilden, Germany) was used. Freshly prepared lutein cells were homogenised (Ultra Turrax, Staufen, Germany half-maximal speed) in the lysis buffer of the kit. The homogenate was processed according to the instructions of the manufacturer. The RNA was checked for intactness by formaldehyde-containing agarose (1·5%) gel electrophoresis (Tontonoz et al. 1994) . The mRNA-PPAR was amplified by reverse transcription polymerase chain reaction (PCR) using a commercial kit (BoehringerMannheim). The construction of the primers (1·2 kb: 5 -CAG TGT GAA TTA CAG CAA ATC TCT and 5 -AAC TTC ACA GCA AAC TCA AAC TTA; 0·76 kb: 5 -AAA ATC AAG TTC AAA CAT ATC ACC and 5 GTT TTT AAA TGC TTT TTC ACA GTA) was based on published PPAR cDNA sequence (Chen et al. 1993 , Zhu et al. 1993 . The PCR was performed according to the conditions defined by computing the primer sequences (35 cycles at 94 C for 30 s, 56 C for 40 s, and 68 C for 70 s). The documentation and the measurement of the electrophoretic migration of the PCR products in comparison with molecular mass standards were performed by computer-aided densitometry (Herolab, Wiesloch, Germany).
PPAR imaging
Cells were fixed and immunostained as described above and spread on slides. Observations were carried out with a fluorescent microscope (Nikon, Dusseldorf, Germany) equipped with a colour video camera (Hamamatsu, Herrsching, Germany) and a computer-aided photomultiplier for fluorescence detection. Fluorescence was simultaneously excited at 360 nm (fluorescence of the nucleus and nucleotides of the cytoplasm) and at 480 nm (fluorescence of the immunostain). The emission was recorded through dichroic mirrors followed by a combination of band pass filters and cut-off filters to record the blue and green (FITC) or orange (phycoerythrin) fluorescence emissions.
Statistical analysis
Unless otherwise stated, experimental data are presented as the mean .. of duplicate measurements of three independent experiments. ANOVA and Tukey's comparison methods were used for comparison among means and Student's t-test when two means had to be compared. ANOVA followed by a least-significant difference test was used in sets of relative data subjected to arcsin transformation prior to statistical analysis. Percentage data obtained by flow cytometry were analysed by 2 analysis (internal program package of the flow cytometer). All other analyses, including the analysis of linear regression, were performed by Jandel Scientific (Graz, Austria) and SAS (NC, USA) computer-aided program packages.
Significance was considered at the P<0·05 level under the condition that the power of the tests displayed by the Jandel program package was sufficient. Curve fitting from data points in dose dependency experiments was made by a three parameter polynomial analysis of regression provided by the SAS program package with the calculation of the ED 50 via the inflexion point.
Results
PPAR visualisation
An immunostained day 12 lutein cell is shown in Fig. 1 . The orange colour of the nucleus compared with the control, omitting the anti-PPAR antibody and incubating the cells with the second, fluorescent antibody (middle cell in Fig. 1 ), provided evidence for nuclear PPAR . In contrast, cytoplasmic PPAR level is low in lutein cells. Figure 2A demonstrates the presence of PPAR mRNA in midphase lutein cells. The electropherogram indicates PPAR cDNA bands produced by reverse transcription PCR from the mRNA of lutein cells. Two primer pairs were used, specifying internal fragments of the PPAR gene and amplifying 760 and 1200 bp. The analysis of PPAR 1 and PPAR 2 was performed at the protein level. The isoforms derive from the same gene by alternate post-transcriptional splicing (Tontonoz et al. 1994) . To identify the isoforms, the proteins of lutein cell lysates were separated by electrophoresis, blotted and immunochemically stained. The densitometric result is shown by Fig. 2B (lane 2). Lutein cells express PPAR 1 with a relative molecular mass of 52 000 and PPAR 2 with one of 55 000. The PPAR forms are phosphorylated as demonstrated by the binding of antibodies to the phosphotyrosine epitope of the proteins (Fig. 2B, lane 3) .
PPAR mRNA and PPAR isoforms
PPAR expression predominates in large lutein cells
The analysis of the PPAR expression in small and large day 12 lutein cells was performed by flow cytometry. The PPAR content of small lutein cells was 39 6% of the content of large lutein cells. The analysis of day 5 and day 12 large lutein cells is shown in Fig. 3 . Day 5 lutein cells developed higher fluorescence intensity than day 12 cells, indicative of a decrease in the PPAR expression during luteal phase progress.
Non-adherent granulosa cells from large follicles were fluorescence negative, in contrast to cells of the follicular wall not further characterised in our study.
PPAR turnover
Day 12 lutein cells were incubated with actinomycin D in order to block de novo synthesis of the PPAR protein.
After 24 h, the portion of PPAR -positive cells was compared with the control without actinomycin D treatment. The results are shown in Table 1 . The percentage of PPAR -positive cells after exposure to actinomycin D was 75% of the control value, indicating a low turnover relative to other regulatory proteins.
The small PPAR protein breakdown may be a function of the cell cycle activity. To examine this hypothesis the cells were incubated with ATA, as we found that lutein cells respond to ATA by increasing the portion of cells with DNA synthesis, measured by flow cytometry and indicated as S-phase cells (Table 2) . ATA was more highly effective in triggering PPAR degradation than actinomycin D and cooperated with actinomycin D in promoting the PPAR degradation (Table 1) , indicative of the role of pathways involved in the cell cycle progression for the breakdown rate of PPAR .
Cell cycle
Lutein cells from the midphase of the ovarian cycle are fully differentiated and low in the portion exhibiting DNA synthesis (Table 2) . ATA promoted the cell cycle activity of lutein cells, demonstrated by a marked increase of the cellular S-phase percentage (Table 2) . In this way, the relationship between PPAR expression and cell cycle progress could be studied. The expression of PPAR decreased during ATA-induced cell cycle progress (Tables 1 and 2 ) whereas the endogenous ligand 15-dPGJ 2 selective for PPAR (Forman et al. 1995) did not affect the cell cycle (Table 2) . However, 15-dPGJ 2 dose dependently reversed the ATA-induced progress of the cell cycle (Table 2) .
PPAR ligands promote progesterone secretion from lutein cells
In order to obtain information about the role of PPAR in steroidogenic activity, the 15-dPGJ 2 dose response of progesterone release from day 12 lutein cells was studied. First, we tested the cell response to naturally occurring stimulation of the steroidogenic activity in comparison with forskolin-triggered, cAMP-mediated activity (Fig. 4C) . The data are indicative of the ability of day 12 lutein cells to respond in vitro to a signal stimulating the progesterone secretion from functionally intact lutein cells. Next, the effect of PPAR ligands was studied ( Fig. 4A  and B) . The cells responded dose dependently to 15-dPGJ 2 by increasing the release of progesterone (1·5-fold as compared with the control) into the culture medium (Fig. 4A) . Then, we compared the action of ATA as a drug exerting a suppressive effect on PPAR expression to the action of natural and pharmacological ligands. ATA inhibited the progesterone secretion. Only in high dosage (>400 nM) did 15-dPGJ 2 abrogate the ATA effect on the progesterone secretion (Fig. 4D) . A selective PPAR ligand, the thiazolidinedione ciglitizone, significantly stimulated the progesterone secretion dose dependently (Fig. 4B ) comparable to the prostaglandin (Fig. 4A) or the dose response to human chorionic gonadotrophin (hCG) (Fig. 4B and C ) mediated by LH receptors. As shown by Fig. 4B , the PPAR ligand did not cooperate with hCG, indicative of a different level of action. In high dosage, however, the ciglitizone was found to be cytotoxic for lutein cells and the progesterone release decreased, indicative of the importance of cell integrity in the maintenance of steroidogenic activity and of a role of PPAR in regulating the activity, rather than other pathways which may be involved in mediating the 15-dPGJ 2 effect.
Finally, the reduction of PPAR by ATA was used to establish the relationship between PPAR expression and progesterone secretion (Fig. 4E) . By decreasing the PPAR expression the progesterone secretion decreased (Fig. 4E) since the slope of the regression line was found to be significant (P<0·05, power of the t-test >0·8). were plotted (the higher the PPAR content per cell, the stronger the cellular fluorescence indicated by shifting the channel number toward an increasing number). The thin-line peaks represent controls, the bold-line peaks PPAR -positive cells. The bold-line peak of (A) differed significantly from the corresponding peak of (B) and both peaks from the control ( 2 analysis, P<0·05). Controls were obtained by incubation of an aliquot from the cell suspension without PPAR -specific antibodies and with fluorogenic antibodies. By calibrating the fluorescence intensity with standard beads, the amount of PPAR per cell was calculated. Large lutein cells gated and analysed by flow cytometry expressed 0·6-5 (day 12) and 6-12 (day 5) fmol PPAR per cell. (C) Granulosa cells aspirated from follicles with a diameter of 5 1 mm were immunostained by a technique identical to that in (A). The cells were fluorescence negative as only a thin-line peak is evident, indicating that PPAR expression is lacking.
Discussion
PPAR is known to be expressed in numerous tissues, albeit at different levels , Braissant et al. 1996 . More recent studies demonstrated PPAR mRNA in oestrogen-dependent reproductive tissues (Nunez et al. 1997 , Sundvold et al. 1997 , and provided evidence for the activation of oestrogen-dependent genes by PPARs (Nunez et al. 1997) . However, the reports only described the expression of PPAR (Nunez et al. 1997) and PPAR (Sundvold et al. 1997) at the mRNA level in ovarian cells. Investigations on PPAR expression in female reproductive cells at the protein level, enabling functional analysis, are seemingly lacking as yet. This paper reports on the expression of PPAR in bovine lutein cells at the mRNA and protein levels. Our results show that the PPAR proteins are active and are involved in the control of progesterone production, a functional differentiation marker of lutein cells. Moreover, the data presented are indicative of another novel role of PPAR , namely the maintenance of a quiescent cell cycle in large lutein cells.
The underlying molecular mechanisms by which PPAR brings about these effects are not fully understood. The majority of studies on PPAR are limited to the adipogenic regulation, as PPAR is believed to play a primary role in the storage and catabolism of lipids in adipose tissue (Kliewer et al. 1997) . Apart from ligands, such as 15-dPGJ 2 , insulin is thought to regulate the activity of PPAR via mitogen-activated protein (MAP) kinase-mediated phosphorylation of PPAR (Hu et al. 1996 , Zhang et al. 1996b . However, the reports concerning cross-talk between insulin and PPAR signalling are inconsistent. The conclusions from a study based on transfection techniques were that insulin synergises with a PPAR ligand and can activate the receptor in a ligandindependent fashion. The mediator of the insulin effect is MAP kinase, which can phosphorylate PPAR (Zhang ANOVA followed by a least significant difference test revealed that differences at least 1·76-fold the mean S.D. of two means were significant (P<0·05). ND=not determined. Table 2 15-dPGJ 2 reverses ATA-induced cell cycle progress. Cell cycle was analysed by flow cytometry. The mean percentage of three independent cell preparations are shown. The coefficients of variation (variation source from three independent experiments with duplicate measurements) were average for G 0 /G 1 4%, M+G 2 9% and S 6%
Cell cycle phases and treatments are significant (ANOVA followed by least-significant difference test, P<0·01, power of the test >0·8). EC 50 was 110 24 nM. Circles stand for means, bars for S.E.M. (B) The thiazolidinedione ciglitizone (), a pharmacological ligand for PPAR , activates progesterone secretion from day 12 lutein cells (incubation for 24 h, 10 6 cells/ml). The differences between control and treatments are significant (ANOVA followed by least-significant difference test, P<0·01, power of the test >0·8). The solvent for ciglitizone was added to the control (0 M ciglitizone). The drug does not cooperate with hCG (). Experiments run in triplicate with duplicate determinations. Symbols stand for means, bars for S.E.M. (C) Dose response to the luteotrophic hormone hCG that binds to LH receptors, inducing a cAMP-mediated rise in progesterone secretion. The differences between lowest and higher dose are significant (ANOVA followed by least-significant difference test, P<0·01, power of the test >0·8). Aliquots of the cell suspension (10 6 /ml) were incubated for 24 h with hCG () at the final concentrations indicated on the abscissa. al. 1996b) . The data from another study, also based on transfection and mutation techniques, provided evidence for the opposite result, namely the inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPAR (Hu et al. 1996) . Our data concerning the role of PPAR phosphorylation are preliminary but suggest that PPAR of midphase lutein cells is phosphorylated. Thereby, PPAR may mediate the observed effects of its ligands, 15-dPGJ 2 and ciglitizone, as a phosphorylated molecule.
Midphase lutein cells are believed to contribute to the major part of the circulating progestins while oestrogens disappear from the circulation (Park-Sarge et al. 1995) . At luteal midphase the bovine corpus luteum is fully developed ( Juengel et al. 1993) . Regression of the corpus luteum can be induced by PGF 2 at this time (Fraser et al. 1995) . Intraluteal infusion of some prostaglandins of the E, I, A, and D series prevents the PGF 2 action without affecting the progesterone level (Zelinski-Wootan & Stouffer 1990) .
Our data provide evidence that the natural ligand of PPAR , 15-dPGJ 2 , and a thiazolidinedione, a selective ligand for PPAR , stimulate the progesterone secretion from lutein cells of the luteal midphase. Moreover, PPAR is expressed at higher level in day 5 than in day 12 lutein cells. One of the most prominent events during the differentiation of lutein cells from follicular precursors is the increased ability to produce and release progestins. Therefore, PPAR (and its ligands) appear to be involved in the differentiation of lutein cells. Support for this contention came from our experimental data using ATA as an inducer of the cell cycle progress and as a stimulator of PPAR breakdown. The observation that a ligand of PPAR , 15-dPGJ 2, is able to reverse the ATA effect provided evidence for the role of active PPAR in the maintenance of a quiescent cell cycle, probably required for lutein cell function. In adipogenic cell systems, PPAR is downregulated by cytokines, such as tumour necrosis factor-(TNF ) produced by activated immunocytes, fibroblasts, and endothelial cells (Zhang et al. 1996a) . In analogy to lutein cells, the decrease is accompanied by dedifferentiation (Zhang et al. 1996a ). We did not use TNF , which may occur naturally in response to the interleukin-1 produced by luteinising granulosa cells (Breard et al. 1998) , as a tool for the downregulation of PPAR in the present study. However, as the PPAR expression appears to be necessary for the maintenance of a differentiated phenotype even in lutein cells, luteolysis may be mediated by activities acting negatively on PPAR expression.
Data from other studies on the 15-dPGJ 2 -PPAR system are limited to transfection/cotransfection assays, which indicate that PPAR chimeras start to respond with reporter production to the PPAR ligand at a concentration of 100 nM with an EC 50 of 2 µM (Forman et al. 1995 , Kliewer et al. 1995 . Interestingly, high doses of PPAR ligand tended to decrease (Kliewer et al. 1995) and significantly decreased (Forman et al. 1995 ) the reporter production. Natural lutein cells respond to the PPAR ligand with a dose-dependent increase of progesterone secretion, exhibiting an EC 50 of about 110 nM. The progesterone secretion declines with a high dose (490 nM) of 15-dPGJ 2 . A similar dose response was observed using a thiazolidinedione as a specific ligand (Forman et al. 1995) for PPAR . The gonadotrophin effect on the progesterone secretion was monitored for comparison with a known stimulatory system acting via LH receptors and cAMP signalling. Gonadotrophin stimulated the progesterone secretion at a level comparable with the PPAR ligand. The lutein cells again responded to a high dose by decreasing the progesterone secretion. The pathways involved in PPAR -mediated action differ from those involved in LH receptor-cAMP-mediated stimulation, since the ligands of PPAR and of LH receptors failed to exhibit antagonistic or cooperative activities. This result is consistent with a report indicating that 15-dPGJ 2 does not mediate its message to PPAR through Ca 2+ -signalling triggered by stimulation of plasma membrane receptors (Kliewer et al. 1994) . The regulatory role of PPAR for the steroidogenic activity may result from the ability of PPARs to activate genes which encode enzymes of the cholesterol biosynthetic pathway, including one of the rate-limiting enzymes, the 3-hydroxy-3-methyl-glutaryl coenzyme A synthase (Rodriguez et al. 1994) , which also seems to be controlled by SREBPs, the other group of transcription factors also involved in cholesterol metabolism and in the activation of genes that encode enzymes of fatty acid metabolism (Brown & Goldstein 1997) . SREBPs-PPAR cross-talk seems to occur in adipocytes as SREBP-mediated transcription may augment the PPAR -mediated transcription . However, studies on transgenic mice provided evidence for SREBP action predominantly in liver cells (Shimano et al. 1996) , which have a markedly higher expression of PPAR than PPAR . Studies on female reproductive cells are apparently lacking.
In summary, our results provide evidence for a relationship between PPAR and progesterone production, a function typical of differentiated lutein cells, and for the inhibition of drug-induced cell cycle progress by a PPAR ligand, suggesting that PPAR appears to coordinate the activity of genes involved in cell cycle progress and in executing the differentiation programme of lutein cells. 
